By otakuyassine3@gmail.com 
Danaher (NYSE:DHR – Get Free Report) had its price target cut by equities researchers at JPMorgan Chase & Co. from $310.00 to $300.00 in a research note issued to investors on Tuesday. The brokerage currently has an “overweight” rating on the conglomerate’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 20.80% from the company’s current price.
Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Guggenheim assumed coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research report on Thursday, October 31st. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Finally, Barclays dropped their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $285.81.
Danaher Price Performance
Shares of NYSE DHR traded down $2.24 during trading on Tuesday, reaching $248.35. The company had a trading volume of 2,393,338 shares, compared to its average volume of 2,872,787. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $179.38 billion, a PE ratio of 47.41, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher has a twelve month low of $225.42 and a twelve month high of $281.70. The stock has a 50-day moving average price of $235.75 and a two-hundred day moving average price of $253.65.
Institutional Trading of Danaher
Several large investors have recently added to or reduced their stakes in the business. Wedge Capital Management L L P NC lifted its holdings in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the period. Meridian Financial Partners LLC raised its holdings in Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares in the last quarter. Kovack Advisors Inc. lifted its position in Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares during the period. Well Done LLC increased its position in shares of Danaher by 1.2% during the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after purchasing an additional 42 shares during the period. Finally, Waypoint Capital Advisors LLC raised its stake in shares of Danaher by 0.9% in the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after buying an additional 42 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
Receive News & Ratings for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.